gip glp 1 dual agonist Tirzepatide, a GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction | Cardiovascular Diabetology Unveiling Tirzepatide's Therapeutic Spectrum: A

In the STEP clinical trials, overweight adults without diabetes lost an average of around 1415% of their body weight after 68 weeks of treatment

Schwingshackl L, Hoffmann G, Lampousi AM, Knppel S, Iqbal K, Schwedhelm C, et al

Stimulation of this receptor leads to weight loss, improved glycemic control in diabetic patients, and improved cardiac and renal outcomes

GLP-1 specifically binds to the glucagon-like peptide-1 receptor (GLP-1R) in the body, directly stimulating the secretion of insulin by pancreatic -cells, promoting proliferation and differentiation, and inhibiting cell apoptosis, thereby exerting a glycemic lowering effect

Phentermine-topiramate ER (Qsymia) combines phentermine with an anticonvulsant that independently promotes weight loss

Zhang R, Packard BA, Tauchi M, DAlessio DA, Herman JP